Drugs / Vibostolimab
Vibostolimab
also known as
MK-7684 · TIGIT INHIBITOR MK-7684 · TIGIT-TARGETING AGENT MK-7684 · Vibostolimab component of mk-7684a
Monoclonal antibody targets TIGIT via inhibition
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02964013 | Dec 2016 → Jul 2024 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT06395090 | Jan 2025 → Jun 2029 | metastatic neoplasm | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04305054 | Jul 2020 → May 2026 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04303169 | Jun 2020 → Sep 2025 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04305041 | Jun 2020 → Aug 2025 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04165070 | Dec 2019 → Feb 2032 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT05005442 | Sep 2021 → Dec 2024 | hematopoietic and lymphoid cell neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT05007106 | Sep 2021 → Aug 2025 | cholangiocarcinoma, endometrium neoplasm, gallbladder neoplasm, gastric neoplasm +7 | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT04725188 | Apr 2021 → Jan 2023 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 35 trials · 4 missed | ||||||
| Phase 3 | NCT05665595 | Jan 2023 → Mar 2024 | melanoma | Merck Sharp & Dohme LLC | Terminated | Missed primary Stop: Business |
| Phase 3 | NCT05298423 | May 2022 → Jun 2026 overdue | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05226598 | Mar 2022 → Sep 2024 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Terminated | Missed primary |
| Phase 3 | NCT05224141 | Mar 2022 → Jun 2024 overdue | small cell lung carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | Missed primary |
| Phase 3 | NCT04738487 | Apr 2021 → Sep 2024 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Terminated | Missed primary Stop: Business |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2024-08-08 | Merck Sharp & Dohme LLC | Results Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer merck.com ↗
At a pre-planned analysis, data showed that the primary endpoint of overall survival (OS) met the pre-specified futility criteria. |
| 2024-06-06 | MSD R&D (China) Co., Ltd. | Results Merck & Co., Inc., Rahway, NJ, USA、切除後高リスク悪性黒色腫に対する術後補助療法としてvibostolimabとペムブロリズマブの配合剤を評価する第3相KeyVibe-010試験の最新情報を公開 msd.co.jp ↗
本日、第3相KeyVibe-010試験のvibostolimabとペムブロリズマブの配合剤の投与群の治療中止を発表しました。 |
| 2024-05-13 | Merck Sharp & Dohme LLC | Results Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma merck.com ↗
At a pre-planned analysis, data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria. |
| 2023-12-07 | Merck Sharp & Dohme LLC | Results Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) merck.com ↗
Vibostolimab/pembrolizumab alone did not show an improvement in median PFS compared to docetaxel alone (2.7 months vs. 3.2 months; HR=1.40 [95% CI, 0.96-2.02]; p=0.9622). |
| 2023-03-16 | Merck Sharp & Dohme LLC | Results Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) merck.com ↗
Results from the open-label arm of the study evaluating MK-7684A alone showed that the coformulation did not reach statistical significance for the primary endpoint of progression-free survival (PFS) and was numerically less effective compared with docetaxel. |
| 2020-09-20 | Merck Sharp & Dohme LLC | Results Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020 merck.com ↗
demonstrated acceptable safety profiles for these two investigational medicines and early signals of anti-tumor activity. |
| 2018-11-07 | Merck Sharp & Dohme LLC | Results Early Phase 1 Data from Merck’s Oncology Pipeline for Investigational Anti-LAG-3 Therapy (MK-4280) and Anti-TIGIT Therapy (MK-7684) to Be Presented at SITC’s 33rd Annual Meeting merck.com ↗
These early studies are providing valuable early insights into the anti-tumor activity for our investigational anti-LAG-3 and anti-TIGIT therapies in patients with advanced and metastatic cancer. |
All press releases naming this drug 9 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vibostolimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05226598 ↗ |
| Known as | MK-7684 | “Coformulation of pembrolizumab (MK-3475) 200mg and vibostolimab (MK-7684) 200mg.” NCT04738487 ↗ |
| Known as | TIGIT INHIBITOR MK-7684 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297785 ↗ |
| Known as | TIGIT-TARGETING AGENT MK-7684 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297785 ↗ |
| Known as | Vibostolimab component of mk-7684a | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297785 ↗ |
| Action | Inhibit | “vibostolimab (anti-TIGIT)” PMID 39775043 ↗ Jan 2025 |
| Modality | Monoclonal antibody | “Vibostolimab, a humanized IgG1 monoclonal antibody, blocks the interaction between TIGIT and its ligands, preventing the immunosuppressive effects of TIGIT.” PMID 39230120 ↗ Sep 2024 |
| Route | Intravenous | “IV infusion” NCT04165070 ↗ |
| Target | TIGIT | “anti-TIGIT (T cell immunoglobulin and ITIM domain) antibody vibostolimab” PMID 34800678 ↗ Nov 2021 |